ADEMPAS FILM-COATED TABLET 2.0mg

Country: Singapura

Bahasa: Inggeris

Sumber: HSA (Health Sciences Authority)

Bahan aktif:

Riociguat micronized

Boleh didapati daripada:

BAYER (SOUTH EAST ASIA) PTE LTD

Kod ATC:

C02KX05

Dos:

2.00mg

Borang farmaseutikal:

TABLET, FILM COATED

Komposisi:

Riociguat micronized 2.00mg

Laluan pentadbiran:

ORAL

Jenis preskripsi:

Prescription Only

Dikeluarkan oleh:

Bayer AG, Leverkusen ( Mfg of bulk product,Pri&SecPackaging,QC & Stability Storage Testing)

Status kebenaran:

ACTIVE

Tarikh kebenaran:

2014-11-24

Risalah maklumat

Page: 1 of 27
Adempas_CCDS07_Jan 2022
1.
NAME OF THE MEDICINAL PRODUCT
Adempas 0.5 mg film-coated tablets
Adempas 1.0 mg film-coated tablets
Adempas 1.5 mg film-coated tablets
Adempas 2.0 mg film-coated tablets
Adempas 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains either 0.5 mg, 1.0 mg,
1.5 mg, 2.0 mg or 2.5 mg
riociguat.
3.
PHARMACEUTICAL FORM
Adempas 0.5 mg film-coated tablets:
White tablets marked with the Bayer cross on one side and 0.5 and an
“R” on the other side.
Adempas 1.0 mg film-coated tablets:
Pale yellow tablets marked with the Bayer cross on one side and 1 and
an “R” on the other
side.
Adempas 1.5 mg film-coated tablets:
Yellow-orange tablets marked with the Bayer cross on one side and 1.5
and an “R” on the
other side.
Adempas 2.0 mg film-coated tablets:
Pale orange tablets marked with the Bayer cross on one side and 2 and
an “R” on the other
side.
Adempas 2.5 mg film-coated tablets:
Red-orange tablets marked with the Bayer cross on one side and 2.5 and
an “R” on the other
side.
Page: 2 of 27
Adempas_CCDS07_Jan 2022
4.
CLINICAL PARTICULARS
4.1
INDICATION(S)
Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4):
Adempas is indicated for the treatment of adult patients with WHO
functional Class II
to III symptoms
•
Inoperable CTEPH,
•
Persistent or recurrent CTEPH after surgical treatment
to improve exercise capacity ( see section 5.1.2).
Pulmonary arterial hypertension (PAH, WHO Group 1):
Adempas is indicated for the treatment of adult patients with WHO
functional class II to III
PAH to improve exercise capacity ( see section 5.1.2).
Efficacy was shown in patients on riociguat monotherapy or in
combination with endothelin
receptor antagonists or prostanoids.
Studies establishing effectiveness included predominately patients
with WHO functional
class II-III and etiologies of idiopathic or heritable PAH or PAH
associated with connective
tissue disease.
4.2
DOSAGE AND METHOD OF ADMINISTRATION
4.2.1
METHOD OF A

Ciri produk

Page: 1 of 27
Adempas_CCDS07_April 2021
1.
NAME OF THE MEDICINAL PRODUCT
Adempas 0.5 mg film-coated tablets
Adempas 1.0 mg film-coated tablets
Adempas 1.5 mg film-coated tablets
Adempas 2.0 mg film-coated tablets
Adempas 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains either 0.5 mg, 1.0 mg,
1.5 mg, 2.0 mg or 2.5 mg
riociguat.
3.
PHARMACEUTICAL FORM
Adempas 0.5 mg film-coated tablets:
White tablets marked with the Bayer cross on one side and 0.5 and an
“R” on the other side.
Adempas 1.0 mg film-coated tablets:
Pale yellow tablets marked with the Bayer cross on one side and 1 and
an “R” on the other
side.
Adempas 1.5 mg film-coated tablets:
Yellow-orange tablets marked with the Bayer cross on one side and 1.5
and an “R” on the
other side.
Adempas 2.0 mg film-coated tablets:
Pale orange tablets marked with the Bayer cross on one side and 2 and
an “R” on the other
side.
Adempas 2.5 mg film-coated tablets:
Red-orange tablets marked with the Bayer cross on one side and 2.5 and
an “R” on the other
side.
Page: 2 of 27
Adempas_CCDS07_April 2021
4.
CLINICAL PARTICULARS
4.1
INDICATION(S)
Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4):
Adempas is indicated for the treatment of adult patients with WHO
functional Class II
to III symptoms
•
Inoperable CTEPH,
•
Persistent or recurrent CTEPH after surgical treatment
to improve exercise capacity ( see section 5.1.2).
Pulmonary arterial hypertension (PAH, WHO Group 1):
Adempas is indicated for the treatment of adult patients with WHO
functional class II to III
PAH to improve exercise capacity ( see section 5.1.2).
Efficacy was shown in patients on riociguat monotherapy or in
combination with endothelin
receptor antagonists or prostanoids.
Studies establishing effectiveness included predominately patients
with WHO functional
class II-III and etiologies of idiopathic or heritable PAH or PAH
associated with connective
tissue disease.
4.2
DOSAGE AND METHOD OF ADMINISTRATION
4.2.1
METHOD